Table 2.

Demographic characteristics of the study cohort by type of transplant

Entire cohort (n = 845)Type of HCT
Autologous (n = 417)Allogeneic (n = 428)
Age (y), median (range)
    Age at transplantation38.2 (21.0-68.6)42.9 (21.0-68.6)35.2 (21.1-62.0)
    Age at study participation46.3 (23.3-73.0)49.1 (23.3-73.0)44.5 (24.2-65.5)
Gender, n (%)
    Male460 (54.4)222 (53.2)238 (55.6)
Race, n (%)
    White681 (80.6)356 (85.4)325 (75.9)
    Hispanic96 (11.4)36 (8.6)60 (14.0)
    Other68 (8.0)25 (6.0)43 (10.1)
Education, n (%)
    High school or less146 (17.3)65 (15.6)81 (19.0)
    High school and some college314 (37.3)142 (34.1)172 (40.4)
    College degree382 (45.4)209 (50.2)173 (40.6)
Household income, n (%)
    ≥$60,000/y387 (48.4)205 (52.0)182 (44.9)
    $20,000-59,999/y307 (38.4)148 (37.6)159 (39.3)
    <$20,000/y105 (13.1)41 (10.4)64 (15.8)
Current health insurance, n (%)
    Uninsured54 (6.5)19 (4.6)35 (8.3)
Duration of follow-up (y), n (%)
    2-5387 (45.8)219 (52.5)168 (39.3)
    6-10285 (33.7)150 (36.0)135 (31.5)
    ≥11173 (20.5)48 (11.5)125 (29.2)
Primary diagnosis
    Hodgkin's lymphoma82 (9.7)79 (18.9)3 (0.7)
    Non–Hodgkin's lymphoma196 (23.2)172 (41.2)24 (5.6)
    Acute lymphoid leukemia52 (6.2)8 (1.9)44 (10.3)
    Acute myeloid leukemia188 (22.2)75 (18.0)113 (26.4)
    Chronic myeloid leukemia223 (26.4)22 (5.3)201 (47.0)
    Aplastic anemia27 (3.2)27 (6.3)
    Other77 (9.1)61 (14.7)16 (3.8)
Relapse risk at HCT, n (%)
    High risk322 (38.2)194 (46.5)128 (30.1)
Conditioning regimen n (%)
    Total body irradiation661 (78.5)281 (67.9)380 (88.8)
Chronic graft vs host disease
    Yes260 (60.9)
Graft vs host disease prophylaxis/treatment
    Cyclosporin A321 (75.0)
Current health, n (%)
    Fair/poor173 (20.6)73 (17.6)100 (23.4)
Concerns for future health, n (%)
    Not concerned40 (4.9)28 (6.8)12 (2.9)